Response to Letter to the Editor: Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Documenti analoghi

• A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  di: Mathias Fiedler, et al.
  Pubblicazione: (2026)
• Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma
  di: Seo Yoon Jang, et al.
  Pubblicazione: (2025)
• Safety and Efficacy of Intra‐Arterial Chemotherapy Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma
  di: Chao Yang, et al.
  Pubblicazione: (2025)
• Prognosis After Discontinued Treatment due to Immune‐Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
  di: Hiromasa Ishihara, et al.
  Pubblicazione: (2025)
• Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
  di: Aarti Bhatia, et al.
  Pubblicazione: (2025)